Genome-wide association studies have linked the T helper 17 (TH17) cell pathway to multiple autoimmune diseases. TH17 cells are potent inducers of tissue inflammation and have been implicated in the pathogenesis of many autoimmune diseases and human inflammatory conditions. Therapeutic interventions with inhibitors of components of this pathway – such as inhibitors of interleukin (IL-)23, IL-17, and the IL-17 receptor – have shown strong clinical benefit in immune disorders such as psoriasis, Crohn’s disease, rheumatoid arthritis, psoriatic arthritis and ulcerative colitis.
Lead Pharma has identified a therapeutic target in the TH17 pathway that remains clinically unaddressed. The relevance of this target in TH17 biology has been validated in human immune cells and in pre-clinical in vivo models, as well as in genetic and patient databases.